Key result
Protein arginine methyltransferases regulate CVD development and progression by methylating histones and transcription factors.
Why the study?
Emerging evidence highlights important roles of PRMTs in cardiovascular diseases, but their therapeutic potential remains incompletely defined due to paradoxical functions and lack of specific inhibitors.
This review highlights the fundamental roles of PRMT-mediated methylation in cardiovascular pathophysiology, identifying them as emerging therapeutic targets for cardiovascular diseases.
PRMTs may emerge as cardiovascular therapeutic targets; leaves open selective inhibitor development and clinical validation.
Methylation, catalyzed by a diverse family of S-adenosylmethionine (SAM)-dependent methyltransferases, is a fundamental biochemical process that regulates the function of proteins, DNA, and RNA. Among these modifications, protein arginine methylation, catalyzed by protein arginine methyltransferases (PRMTs), represents a critical post-translational mechanism regulating transcription, DNA repair, RNA splicing, and signal transduction. Emerging evidence highlights important roles of PRMTs in cardiovascular diseases (CVDs); however, current research is limited by several challenges, including the paradoxical and context-dependent functions of individual PRMTs and the lack of highly specific inhibitors or activators, leaving their therapeutic potential incompletely defined. This review summarizes the classification, structure, and functional characteristics of methyltransferases, with a particular focus on PRMTs and their roles in normal physiology and diverse CVDs. We integrate current knowledge to provide a comprehensive understanding of how PRMTs contribute to cardiovascular pathophysiology by methylating histones, transcription factors, and other functional proteins. Collectively, PRMTs emerge as pivotal regulators in CVD development and progression. Future studies should prioritize resolving the functional duality of specific PRMTs, developing targeted precision therapeutics, and elucidating the roles of less-characterized family members in CVDs.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2026) conducted a review in Cardiovascular diseases. Protein Arginine Methyltransferases (PRMTs) was evaluated. Protein arginine methyltransferases emerge as pivotal regulators in cardiovascular disease development and progression by methylating histones, transcription factors, and other functional proteins.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: